Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia. (2nd January 2018)
- Record Type:
- Journal Article
- Title:
- Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia. (2nd January 2018)
- Main Title:
- Early pregnancy protein multiplex screening reflects circulating and urinary divergences associated with the development of preeclampsia
- Authors:
- Martinez-Fierro, Margarita L
Castruita-De La Rosa, Claudia
Garza-Veloz, Idalia
Cardiel-Hernandez, Rosa M
Espinoza-Juarez, Marcela A
Delgado-Enciso, Ivan
Castañeda-Lopez, Maria E
Cardenas-Vargas, Edith
Trejo-Vázquez, Fabiola
Sotelo-Ham, Elma I
Castañeda-Miranda, Rodrigo
Cid-Baez, Miguel A
Ortiz-Rodriguez, Jose M
Solis-Sanchez, Luis O
Aviles, Angelica Garcia
Ortiz-Castro, Yolanda - Abstract:
- ABSTRACT: Background : Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective : To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods : We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex Pro TM Human Cancer Biomarker Panels 1 and 2. Results : The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups ( p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8–29.8 times in the study population. Conclusion : The proteinsABSTRACT: Background : Preeclampsia, a pregnancy disorder characterized by hypertension and proteinuria, represents the leading cause of fetal and maternal morbidity and mortality in developing countries. The identification of novel and accurate biomarkers that are predictive of preeclampsia is necessary to improve the prognosis of patients with preeclampsia. Objective : To evaluate the preeclampsia predictive value of 34 angiogenic-related proteins. Methods : We performed a nested cohort case-control study of pregnant women. The profile of the 34 proteins was evaluated at 12, 16, and 20 gestational weeks (GWs), using urine/plasma from 16 women who developed preeclampsia and 20 normotensive pregnant controls by Bio-Plex Pro TM Human Cancer Biomarker Panels 1 and 2. Results : The urine concentration of soluble epidermal growth factor receptor (sEGFR), hepatocyte growth factor (HGF), angiopoietin-2 (ANG-2), endoglin (ENG), soluble fas ligand (sFASL), interleukin 6 (IL-6), placental growth factor (PLGF), and vascular endothelial growth factor A (VEGF-A) at 12 GW, prolactin (PRL), ANG-2, transforming growth factor alpha (TGF-α), and VEGF-A at 16 GW, and soluble IL-6 receptor alpha (sIL-6Rα), ANG-2 and sFASL at 20 GW, were different between groups ( p < 0.05). The concentration cut-off values calculated in this study for the mentioned proteins, predicted an increased risk to developing preeclampsia in a range of 3.8–29.8 times in the study population. Conclusion : The proteins sEGFR, HGF, ANG-2, sFASL, IL-6, PLGF, VEGF-A, PRL, TGF-α FGF-b, sHER2/Neu sIL-6Rα, ENG, uPA, and insulin-like growth factor binding protein 1 (IGFBP-1), were predictive of the development of preeclampsia and their use as markers for this disease should be considered. … (more)
- Is Part Of:
- Hypertension in pregnancy. Volume 37:Number 1(2018)
- Journal:
- Hypertension in pregnancy
- Issue:
- Volume 37:Number 1(2018)
- Issue Display:
- Volume 37, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 37
- Issue:
- 1
- Issue Sort Value:
- 2018-0037-0001-0000
- Page Start:
- 37
- Page End:
- 50
- Publication Date:
- 2018-01-02
- Subjects:
- Angiogenesis -- biomarkers -- cancer -- placenta -- preeclampsia -- screening -- urine
Hypertension in pregnancy -- Periodicals
Pregnancy -- Complications -- Periodicals
618.3261 - Journal URLs:
- http://informahealthcare.com/journal/hip ↗
http://informahealthcare.com ↗ - DOI:
- 10.1080/10641955.2017.1411946 ↗
- Languages:
- English
- ISSNs:
- 1064-1955
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4352.635260
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 5845.xml